Kiyatec Inc. announced a closing of its Series C funding round totaling US$18 million from new and existing investors. New investor Bruker Nasdaq: BRKR led the financing and was joined by existing investors Seae Ventures, VentureSouth, and LabCorp NYSE: LH. Use of funds will focus on accelerating adoption of the company's commercially available clinical testing and preclinical pharma services, which add value across the life cycle of successful cancer drugs.